Glenmark's US arm launches Olanzapine Injection 10 mg/vial in US market
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the US market. The product is bioequivalent and therapeutically equivalent to Zyprexa IM Injection 10 mg/vial of Cheplapharm Registration GmbH (NDA 021253). Per IQVIA data for the 12 months ending May 2026, the Zyprexa IM Injection market had annual sales of about 25.4 million US dollars. Management says the launch supports growth of its injectables portfolio and institutional channel presence.
Expands US injectables portfolio. Target market is about 25.4 million US dollars annually per IQVIA. Modest size but strengthens institutional channel.